trending Market Intelligence /marketintelligence/en/news-insights/trending/U2ur-oAHTxeuPV0kUexPIg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bristol-Myers, Eisai collaborate to develop cancer therapies using gene editing

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Bristol-Myers, Eisai collaborate to develop cancer therapies using gene editing

Bristol-Myers Squibb Co. and Japan's Eisai Co. Ltd. will collaborate to develop cancer immunotherapies using gene editing of ribonucleic acid, which plays a part in gene coding, regulation and expression.

The collaboration will use the ribonucleic acid, or RNA, splicing platform that was developed by Eisai's Cambridge, Mass.-based unit H3 Biomedicine Inc. to develop therapies for cancer.

H3 is researching the potential of the RNA splicing platform to develop potential first-in-class therapies that would direct the immune system to target cancer cells. H3 President and Chief Data Sciences Officer Lihua Yu said the collaboration will help the company better understand whether the platform can help enhance the immune system's ability to fight cancer.

Under the agreement, Bristol-Myers and H3 will jointly research the program, but the New York-based biopharmaceutical giant will be responsible for developing and commercializing selected compounds. Eisai will retain an option to co-develop and co-commercialize certain compounds emerging from the collaboration. H3 is eligible to receive an up-front fee, development, regulatory and sales milestones, as well as certain royalties.

Financial terms of the agreement were not disclosed.